In vitro resistance to anthracyclines is related to a poor prognosis in childhood acute lymphoblastic leukemia (ALL), but the underlying mechanisms are poorly understood. Using flow cytometry, we studied the contribution of daunorubicin (DNR) accumulation and retention, cell size, expression of the major vault protein/lung resistance protein (LRP), P-glycoprotein (Pgp) and multidrug resistance-associated protein (MRP) to the cytotoxicity of DNR (by MTT assay) in childhood ALL. The accumulated and retained DNR content was not related to the degree of DNR resistance, nor did the content differ between 53 initial and 20 relapse ALL samples (P Ͼ 0.05), although the latter were median two-fold more resistant to DNR (P ‫؍‬ 0.004). 
Introduction
The mechanisms of drug resistance are poorly understood in childhood acute lymphoblastic leukemia (ALL), despite the fact that approximately 25% of the children suffer from a relapse. 1, 2 In vitro resistance of leukemic cells to the anthracycline daunorubicin (DNR) is related to a poor prognosis in children with ALL. 3, 4 Resistance to DNR may be caused by reduced intracellular drug levels, intracellular entrapment of drugs, detoxification of drugs and by reduced quantities or modifications of intracellular drug target(s).
Anthracyclines enter the cell by passive diffusion, most likely in the uncharged form. 5, 6 The transport rate depends on the hydrophobicity of the drug: more lipophilic anthracyclines such as idarubicin enter the cell faster compared with the less hydrophobic DNR. 7 Within the cell, most of the drug molecules become protonated due to the lower intracellular pH. The positive charge of anthracyclines impairs the passive drug efflux out of the cell and improves the drug retention in the cytoplasm or intracellular compartments. In acidic compartments such as lysosomes, anthracyclines may be entrapped at very high concentrations compared with the surrounding cytoplasm. 5 Drug accumulation defects may be caused by altered membrane properties which may hamper the passive transport of uncharged DNR across the plasma membrane. 8 The intracellular DNR levels may also be lowered by extrusion of the (charged) molecules out of the cell by efflux-mediating proteins, such as the P-glycoprotein (P-gp) and the multidrug resistance-associated protein (MRP). 9, 10 The cytotoxic action of DNR and other anthracyclines may also be prevented by mechanisms that redistribute the drug from its target and that sequester the drug into subcellular compartments, eg vesicles. [11] [12] [13] A putative drug resistance protein that may contribute to the intracellular transport and/or sequestration of drugs may be the recently identified major vault protein/lung resistance protein (LRP). 14, 15 In childhood ALL, two studies reported a relationship between P-gp expression and retention of the marker molecule rhodamine 123, 16, 17 whereas in another study no correlation was found between P-gp expression and DNR accumulation. 18 This underlines the contradictory results that have been reported about the clinical relevance of P-gp in childhood leukemia. 16, [18] [19] [20] [21] [22] It is unknown whether MRP and LRP are related to the intracellular DNR levels in childhood leukemic cells. Moreover, it is unknown whether the intracellular DNR level correlated with the cytotoxicity of this drug in childhood ALL.
Here, we report the relationship between the accumulation and retention of DNR, cell volume, expression of P-gp, MRP, LRP and in vitro resistance to DNR in childhood ALL.
Materials and methods

Leukemic cell samples
Bone marrow and peripheral blood samples were collected from 60 children at initial diagnosis (untreated) and 25 unrelated children at relapse of ALL. Within 24 h of sampling, the mononuclear cells were separated by Lymphoprep (density 1.077 g/ml; Nycomed Pharma, Oslo, Norway), centrifuged at 480 g for 15 min at room temperature. The percentage of leukemic cells was morphologically determined by May-Grü nwald-Giemsa (Merck, Darmstadt, Germany) staining of cytospin preparations. When necessary, the percentage of leukemic cells was enriched to Ͼ80% using monoclonal anti-bodies linked to magnetic beads (Dynabeads; Dynal, Oslo, Norway) to eliminate contaminating cells. 23 Cells were resuspended in RPMI 1640 (Dutch modification without l-glutamine; Gibco BRL, Breda, The Netherlands) supplemented with 20% fetal calf serum (Gibco BRL), 2 mm l-glutamine (ICN Biomedicals, Costa Mesa CA, USA), 5 g/ml insulin, 5 g/ml transferrin, 5 ng/ml sodium selenite (Sigma, St Louis, MO, USA) and antibiotics.
Cell lines
The human epidermoid carcinoma cell line KB3-1 and the sublines KB8 and KB8-5 were used to validate the flow cytometric detection of DNR accumulation and retention. KB8 and KB8-5 cells are respectively two-and five-fold more resistant to DNR compared with the parental KB3-1 cells. Both KB8 and KB8-5 cells accumulate and retain less DNR compared with parental cells. 24 
DNR accumulation and retention
Leukemic cells at a concentration of 0.5 × 10 6 cells/ml were incubated with DNR (Cerubidine; Rhô ne Poulenc Rorer, Amstelveen, The Netherlands) in humidified air and 5% CO 2 at 37°C. The accumulation of DNR was determined at several time-points during a continuous exposure to 10 g/ml DNR, unless other concentrations are indicated. To study the retention, cells were first loaded with 10 g/ml DNR for 1 h at 37°C. Cells were washed in ice-cold PBS and resuspended in a pre-warmed DNR-free medium, after which the efflux started. The retained amount of DNR was determined at several time-points, including the start of efflux (t = 0). Each aliquot (200 l) was washed immediately in ice-cold PBS. The samples were kept on ice until the intracellular DNR fluorescence was measured by flow cytometry (FACScan; Becton Dickinson, Erembodegem, Belgium). DNR was excitated by an argon laser at 488 nm and the orange/red fluorescence signal was collected through a 585/42 bandpass filter set (FL-2 height). The instrument settings for FL-2 height, forward scatter (FSC) and sideward scatter (SSC) were kept constant between two services of the flow cytometer. The data were analyzed using LYSYS II software (Becton Dickinson). Viable leukemic cells were gated based on FSC and SSC characteristics. The percentage of gated cells corresponded well with the percentage of viable cells morphologically determined by trypan blue exclusion.
The intracellular DNR content was determined by the mean fluorescence intensity of gated leukemic cells, and was expressed in arbitrary units (AU) on a log-scale. All measurements were normalized using propidium iodide labeled reference beads (Flow Cytometry Standards Corporation, San Juan, PR), except for the 12 samples initially used to determine the optimal incubation concentration of DNR. These measurements were normalized using R-phycoerythrin labeled beads (CaliBrite; Becton Dickinson). The FSC of gated leukemic cells normalized by the FSC of the above-mentioned reference beads was linearly related to the cell diameter measured by the Elzone 80 xy Electrozone/Celloscope (Particle Data, Elmhurst, IL, USA; R 0.75, P Ͻ 0.0001), and was used as a relative measure of cell volume (FSC 3 ) in this study similar to the value for cell volume used by others. [25] [26] [27] The intracellular DNR concentration was obtained by dividing the intracellular DNR content by the relative cell volume (AU/FSC 3 ). The percentage of DNR retention was calculated by dividing the DNR-fluorescence retained in the cell after a period of efflux by the DNR-fluorescence present at the start of efflux (t = 0) × 100%. Cell volume, intracellular DNR content, intracellular DNR concentration and % DNR retention did not differ between leukemic cells originating from bone marrow or peripheral blood samples. Therefore, these data were pooled for further analysis.
Expression of drug resistance proteins
The drug resistance proteins were detected using an optimized and reproducible flow cytometric method for childhood ALL cells as previously described.
28 P-gp expression was demonstrated by the monoclonal antibodies C219 (mouse IgG2a, 10 g/ml; Centocor Diagnostics, Malvern, PA, USA) and MRK16 (mouse IgG2a, 5 g/ml; Kamiya Biomedical Company, Thousand Oaks, CA, USA). MRP was detected by MRPm6 (mouse IgG1, 10 g/ml) and MRPrl (rat IgG2a, 1.7 g/ml).
29 LRP56 (mouse IgG2b, 0.7 g/ml) was used to determine LRP expression.
14 Non-specific isotype-matched antibodies (Dako, Glostrup, Denmark) were used at the same IgG concentration as the specific antibodies. After fixation with 0.74% formaldehyde solution in acetone for 10 s at room temperature or 100% methanol for 15 min at −20°C (for MRPm6 only), cells were incubated with the primary antibody for 45 min, washed, and incubated with fluorescein isothiocyanate (FITC) conjugated rabbit anti-mouse F(abЈ) 2 or anti-rat antibodies (1:50 and 1:500, respectively; Dako) for 30 min at room temperature. The amount of FITC-labeling was detected by flow cytometry (FACScan); green fluorescence was collected through a 530/30 nm bandpass filter set using log-mode amplification (FL-1 height). The flow cytometry data were analyzed using LYSYS II software. Leukemic cells were gated based on FSC and SSC characteristics, and the fluorescence intensity of this population was expressed in arbitrary units on a log-scale. As a measure for the intensity of staining the fluorescence index (FI) was used, which represents the ratio between the mean fluorescence intensity of cells stained with the specific antibody and that of cells stained with the isotypematched control antibody. No difference between the FI of leukemic cells isolated from bone marrow or peripheral blood samples was observed, therefore these data were pooled for further analysis.
In vitro drug resistance assay
The MTT assay conditions were the same as described before. 23, 30, 31 The following drugs were tested: DNR (Cerubidine; Rhô ne-Poulenc Rorer), idarubicin (Zavedos; Pharmacia and Upjohn, Woerden, The Netherlands), prednisolone disodiumphosphate (Bufa Pharmaceutical Products, Uitgeest, The Netherlands), vincristine (Oncovin; Eli Lilly, Amsterdam, The Netherlands), l-asparaginase (Medac, Hamburg, Germany) and etoposide (Vepesid; Bristol Myers, Weesp, The Netherlands). To summarize the test principles, cells were cultured in 96-well plates in the absence (control) or presence of a drug. Each drug was tested at six different concentrations in duplicate. After 4 days of culture in humidified air containing 5% CO 2 at 37°C, MTT (3-[4,5-dimethylthiazol-2-y1]-2,5-diphenyl tetrazoliumbromide; Sigma) was added to each well at a final concentration of 0.45 mg/ml. Subsequently, cells were incubated with MTT for 6 h at 37°C.
In this period, viable cells can reduce the yellow MTT resulting in a purple formazan product. The formazan crystals were dissolved using acidified isopropanol and the quantity of reduced product was measured spectrophotometrically at 562 nm (Bio-Kinetics Reader EL-312, Bio-Tek Instruments, Winooski, VT, USA). The optical density (OD) at 562 nm is linearly related to the number of viable ALL cells. 30 Reproducible test results were obtained when, after 4 days of culture, the control wells without drug contained Ͼ70% leukemic cells and the OD of these wells (adjusted for blank values) was higher than 0.050 arbitrary units. 23, 32 When a sample met these criteria, the leukemic cell survival at each drug concentration was calculated by the equation: leukemic cell survival = (OD drug containing well/OD wells without drug) × 100% (after subtraction of relevant blank values). The drug concentration lethal to 50% of the cells, ie the LC 50 value, was used as measure for the in vitro drug cytotoxicity. No difference in LC 50 values was observed between bone marrow and peripheral blood samples. 30 Hence, these data were pooled for further analysis.
Statistics
Differences in variables between two groups were analyzed using the Mann-Whitney U test, adjusted for tied ranks. Correlation coefficients were calculated using the Spearman's rank correlation coefficient (Rs). A P value Ͻ0.05 was considered to be statistically significant (two-tailed tested).
Results
Accumulation and retention of DNR: validation of experimental conditions
The accumulation of DNR in ALL cells was linearly related to the extracellular DNR concentration up to at least 10 g/ml (Figure 1) . A DNR concentration of 10 g/ml was chosen for further experiments because at this concentration the differences in the accumulated DNR contents between 12 patients (n = 7 at presentation, n = 5 at relapse) could be well discriminated ( Figure 1) .
To validate the sensitivity of the method, the accumulation and retention of 10 g/ml DNR was measured in parental KB3-1 and DNR resistant KB8 and KB8-5 cells (respectively two-and five-fold resistant compared with KB3-1 cells). Both KB8 and KB8-5 accumulated and retained less DNR compared with the parental KB3-1 cells (Figure 2) , which is in agreement with the known characteristics of these cell lines. 24 These data also show that accumulation and retention differences could be demonstrated between parental and lowresistant KB8 cells. The resistance ratio of KB8 cells for DNR, ie two-fold, is comparable with the DNR resistance ratios observed in childhood ALL samples. 4, 31 Therefore, the experimental conditions were further used to study the relationship between the accumulation and retention of DNR and the in vitro resistance to DNR in leukemic cells of children with ALL.
Accumulated and retained DNR content in ALL cells
Accumulation and retention of DNR was measured in 53 initial and 20 relapsed childhood ALL samples. Figure 3 shows that both the accumulation and the retention of DNR reached Relationship between the intracellular accumulated DNR content (arbitrary units, AU) and the extracellular applied DNR concentration (g/ml). Cells were incubated for 1 h with the indicated drug concentrations. Each symbol represents one patient. The line of best fit is drawn through the median accumulated DNR content of 12 patient samples. a plateau after 3 h of incubation. The accumulated and retained intracellular DNR content of initial and relapse samples did not differ (P Ͼ 0.05 at all time-points). However, relapse samples were median two-fold more resistant to DNR compared with initial samples (median (25-75th percentile) LC 50 values for relapsed patients 0.165 (0.077-0.389) g/ml and 0.077 (0.055-0.098) g/ml for initial patients, P = 0.004), as has also been demonstrated before in a larger series of patients. 31 The in vitro DNR cytotoxicity did not significantly correlate with the accumulated or retained DNR content at any time-point studied (P Ͼ 0.05 for each Rs).
Accumulated and retained DNR concentration in ALL cells
Relapsed cells were median 1.5-fold larger than cells obtained at initial diagnosis (P = 0.001; Figure 4 ). The cell volume was significantly related to DNR and idarubicin resistance (Rs 0.32, P = 0.012 and Rs 0.46, P = 0.011, respectively) but not to the cytotoxicity of prednisolone (Rs 0.27, P Ͼ 0.05), vincristine (Rs − 0.11, P Ͼ 0.05), l-asparaginase (Rs − 0.01, P Ͼ 0.05) and etoposide (Rs 0.12, P Ͼ 0.05). Larger cells accumulated and retained more DNR than smaller cells (for example after 1 h of accumulation, Rs 0.50, P Ͻ 0.0001; retention after 1 h, Rs 0.37, P = 0.002).
The leukemic cell volume was used to calculate the intracellular DNR concentration from the intracellular DNR content. As shown in Figure 5 for initial and relapsed patients together, resistance to DNR inversely correlated with the accumulated DNR concentration (Rs −0.44, P = 0.0007) and the retained DNR concentration (Rs −0.33, P = 0.016) measured after 1 h. Significant correlations were also found at all other time-points studied. Among initial ALL patients only, correlation coefficients were similar to the total group (1 h accumulation Rs −0.41, P = 0.009; retention Rs −0.29, P = 0.09) whereas among the smaller group of relapse samples the correlation coefficients were weak and not significant (1 h accumulation Rs −0.10, P Ͼ 0.05; retention Rs −0.17, P Ͼ 0.05).
The intracellular DNR concentration was significantly lower in relapse compared with initial ALL cells at all time-points: for example median 1.4-fold (P = 0.003) for the accumulation and median 1.3-fold (P = 0.03) for the retention measured after 1 h. The percentage of retained DNR after a period of efflux compared to the start of efflux (t = 0 min) did not differ between initial and relapse samples (P Ͼ 0.05), neither was the percentage of retention related to the in vitro DNR cytotoxicity (P Ͼ 0.05 for each Rs). 
Intracellular DNR concentration and drug resistance protein expression
The accumulated and retained DNR concentration did not significantly correlate with the fluorescence index (FI) using the antibodies C219 or MRK16 for P-gp (−0.14 Ͻ Rs Ͻ +0.14, P Ͼ 0.05) and MRPm6 or MRPr1 for MRP (−0.16 Ͻ Rs Ͻ +0.17, P Ͼ 0.05) at all measured time-points. In the plateau phase of accumulation, the intracellular DNR concentration inversely correlated with the expression of LRP (t = 180 min: Rs −0.33, P = 0.031; t = 300 min: Rs −0.36, P = 0.012, Figure 6 ). Although the correlation between LRP expression and the retained DNR concentration at each time-point was always stronger than observed for P-gp and MRP, none of these correlations was significant. No significant correlations were found between the % DNR retention and the expression of P-gp, MRP or LRP.
Expression of LRP, P-gp and MRP did not differ between initial and relapse samples (P Ͼ 0.05). Expression of LRP, but not of P-gp and MRP, correlated with resistance to DNR in childhood ALL (Rs 0.33, P = 0.03, n = 42). These data are in agreement with data reported elsewhere.
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Discussion
The capacity of cells to accumulate and retain a drug may contribute to the efficacy of a drug to kill the cell. In the present study, the total intracellular DNR content was not related to in vitro DNR resistance in ALL cells. However, larger cells were in vitro more resistant to DNR. When the intracellular DNR content was corrected for cell volume, the intracellular DNR concentration inversely correlated with DNR resistance, both when the accumulation and retention of the drug was studied. These data show that not the intracellular content but rather the intracellular concentration may be important for the cytotoxic effect of DNR in childhood ALL. The need for cell volume corrections has been reported before by Ross et al, 26 who showed that the discrimination in accumulation and retention of DNR between drug-resistant and drug-sensitive cell lines could be improved by cell volume corrections. However, in the majority of reports that use flow cytometry to determine the intracellular drug levels only the drug content is evaluated. The present study illustrates that the importance of intracellular drug levels may be underestimated when only the drug content is used.
In the present study, cell volume was larger and the intracellular DNR concentration was lower in relapsed cells compared with initial ALL cells. Larger cells at relapse have been demonstrated before and, moreover, cell size at initial diagnosis correlated with prognosis in childhood ALL. 34, 35 At present, a satisfying explanation for the increased cell volume at relapse compared with initial diagnosis is missing. In the Relationship between resistance to DNR (LC50; g/ml) and the intracellular DNR concentration (conc; AU/FSC context of the present data, it might be that the intracellular anthracycline concentration at initial diagnosis was not sufficient to kill the larger cells and that regrowth of these cells gave rise to reoccurrence of the disease. The reduced intracellular DNR concentration in relapse compared with initial ALL cells may contribute to the two-fold resistance to DNR observed in relapse ALL samples, which was found in this study and in an earlier study including a larger number of childhood ALL samples. 31 The cell volume correlated with resistance to the tested anthracyclines, ie DNR and idarubicin, but not to other classes of drugs such as prednisolone, vincristine, l-asparaginase and etoposide. In a pilot study, the intra- cellular concentration of DNR and idarubicin correlated with each other in childhood ALL cells (data not shown). This suggests that the intracellular concentration may also be important for the cytotoxic effect of anthracyclines other than DNR and could explain the cross-resistance that is often observed for several anthracyclines such as DNR, idarubicin, doxorubicin, aclarubicin and the anthracenedione mitoxantrone in samples of children with ALL. 36, 37 The question remains which mechanism contributes to the lower intracellular DNR concentration in childhood ALL. The intracellular concentration may be lowered by extrusion of the drug out of the cell by efflux pumps, such as P-gp and MRP. However, in the present study the intracellular DNR concentration was not related to the expression of P-gp and MRP in childhood ALL. Moreover, resistant cells did not demonstrate an enhanced efflux of DNR out of the cell compared with sensitive cells, since the percentage of retention was not related to DNR resistance. We previously showed that the modulators PSC 833, cyclosporin A and verapamil do not increase the intracellular DNR accumulation in childhood ALL. 18, 38 Moreover, the expression of P-gp or MRP was not linked with in vitro resistance to DNR, vincristine or etoposide in childhood leukemia. 33 The expression of P-gp and MRP also did not differ between initial and relapse pediatric ALL samples nor between ALL and normal bone marrow and peripheral blood cells, whereas normal peripheral blood lymphocytes and (heterogeneous) bone marrow cells are extremely resistant to DNR and other drugs. 30, 33 In summary, these data suggest that P-gp and MRP do not play a major role in the reduced intracellular DNR concentration observed in DNRresistant leukemic cells of children. In adult acute leukemia, ie mainly acute myeloid leukemia, expression of P-gp (but not of MRP) is related to reduced intracellular drug levels and/or a poorer prognosis of patients. [39] [40] [41] [42] This relationship is less evident for adults suffering from ALL and suggest that P-gpmediated drug resistance may be more related to the (sub)type of leukemia than with the age of the patient. 39 In contrast to studies using highly selected cell lines generated by drug exposure or transfection of the gene of interest, the study of mechanisms contributing to resistance in clinical samples is always restricted by the heterogeneity between patients. In addition, resistance to drugs depends on multiple factors of which the actual contribution to resistance may vary between patients and between drugs. This also weakens the strength of a correlation and emphasizes that studies about mechanisms of resistance in patients should include sufficient samples to be able to detect the significance of such weak correlations.
In the present study, expression of the major vault protein LRP correlated weakly but significantly with the intracellular DNR concentration measured in the plateau phase of accumulation (after 180 to 300 min of incubation). In contrast, LRP expression was not related to the retained DNR concentration. Inconsistency between accumulation and retention data with respect to expression of LRP has also recently been demonstrated in a mixed population of adult acute myeloid leukemia, ALL and chronic myeloid leukemia. 43 However, the use of two different agents to study the accumulation, ie DNR, and retention, ie rhodamine 123, may interfere with the interpretation of that study. In a subsequent study of 96 adults with de novo AML, the difference in DNR accumulation between LRP-positive and LRP-negative cells was confirmed but no data about DNR retention were included. 42 In SW1573 non-small cell lung cancer cells, LRP-positive 2R120 cells accumulated less DNR compared with LRP-negative parental cells whereas this difference was less pronounced for the retention of DNR. 14, 44 An explanation for the observed difference between DNR accumulation and retention with respect to LRP expression is difficult and requires more knowledge about the function of LRP. LRP contributes to more than 70% of the mass of vault particles 15 which may play a role in the nuclear-cytoplasmic and vesicular transport of molecules. 45, 46 Recently, a higher number of vault particles was found in drug-resistant cell lines compared with parental cells. 47 LRP/vaults may mediate the transport of drugs into vesicles, which may sequestrate the drug from its cellular target and/or may result in exocytosis of the drug. If intracellular concentrations are getting too high for the cell, exocytosis of vesicles might be triggered (eg after prolonged continuous exposure to DNR). The granular staining pattern of LRP in several drugresistant cell lines, 14 in adult acute myeloid leukemia 48, 49 and in childhood ALL 33, 50 may be indicative for a vesicular localization of LRP. Another explanation for LRP/vaults mediated drug resistance may be the redistribution of the drug from the nucleus (drug target) to the cytoplasm, which may be followed by sequestration in vesicles and/or extrusion out of the cell. In this respect, the ratio between the doxorubicin content of the nucleus and cytoplasm (N/C ratio) was lower in LRP-positive SW1573/2R120 cells than in LRP-negative parental cells. 11, 14 The N/C ratio of DNR in childhood ALL cells is difficult to measure accurately because these cells only contain a rim of cytoplasm in contrast to a large nucleus. Moreover, the fluorescence of DNR in the nucleus will also be reflected in the surrounding cytoplasm which hampers the measurements of DNR in the cytoplasm only.
Although the physiological role of LRP is not yet known, the relationship between LRP expression and a poor prognosis in advanced ovarian carcinoma and adult AML implies a possible role for LRP in drug resistance. 41, 48, 49, 51, 52 However, recent reports also suggest that LRP may not be associated with a poor clinical response in adult AML. 42, [53] [54] [55] This controversy may be explained by differences in the treatment that the patients received and by differences in the technique used (flow cytometry, 42, [53] [54] [55] immunocytochemistry 41, 48, 49 and RT-PCR). 51 From our own experience we know that the reproducibility of staining results is good only if one studies the protein expression using standardized conditions (eg purity of the patient sample always being Ͼ80% leukemic cells, avoiding repeated thawing/freezing of the antibodies, including control cell lines or a control patient, etc). In our hands, the correlation between immunocytochemical and flow cytometric detection of LRP was moderate in leukemic cells of children with ALL (Rs 0.5, P Ͻ 0.0001, n = 76; data not shown), which was similar to what was found in adult AML (Rs 0.45, P = 0.03). 56 Although both techniques detect the expression level of proteins, the subjective classification into negative, weakly positive or positive staining using immunocytochemistry gives less variation in staining scores (except observer variation) compared with the dynamic range of fluorescence indices obtained using flow cytometry. In an extensive analysis of the reproducibility of both techniques for drug resistance protein detection we observed the least assay variation using flow cytometry. 28 We previously showed that expression of LRP correlated with resistance to DNR but not vincristine and etoposide in a large series of children with ALL. 33 In the present study we showed that the expression of LRP inversely correlated with the intracellular accumulated DNR concentration. In conclusion, both LRP and the intracellular DNR concentration may contribute to DNR resistance in childhood ALL. The strength of the observed correlations also indicates that resistance to these drugs is not caused by only one single mechanism. Further knowledge about the physiological role of LRP/vaults is warranted to explain whether LRP also actually contributes to resistance or just represents an epiphenomenon associated with cellular resistance to DNR in childhood ALL.
